Arecor Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Arecor Therapeutics şirketinin toplam hissedar öz sermayesi £5.1M ve toplam borcu £0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla £10.4M ve £5.3M dir.

Anahtar bilgiler

Borç/özkaynak oranı

UK£0

Borç

Faiz karşılama oranı	n/a
Nakit	UK£2.55m
Eşitlik	UK£5.08m
Toplam yükümlülükler	UK£5.29m
Toplam varlıklar	UK£10.37m

Son finansal sağlık güncellemeleri

Companies Like Arecor Therapeutics (LON:AREC) Are In A Position To Invest In Growth

Jul 16

Will Arecor Therapeutics (LON:AREC) Spend Its Cash Wisely?

Mar 15

Recent updates

Companies Like Arecor Therapeutics (LON:AREC) Are In A Position To Invest In Growth

Jul 16

Will Arecor Therapeutics (LON:AREC) Spend Its Cash Wisely?

Mar 15

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: AREC 'nin kısa vadeli varlıkları ( £6.4M ) kısa vadeli yükümlülüklerini ( £4.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: AREC şirketinin kısa vadeli varlıkları ( £6.4M ) uzun vadeli yükümlülüklerini ( £625.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: AREC borçsuzdur.

Borcun Azaltılması: AREC un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: AREC son raporlanan serbest nakit akışına göre 5 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: AREC serbest nakit akışı tahminlerine göre 11 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Arecor Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Companies Like Arecor Therapeutics (LON:AREC) Are In A Position To Invest In Growth

Will Arecor Therapeutics (LON:AREC) Spend Its Cash Wisely?

Recent updates

First half 2024 earnings released: UK£0.15 loss per share (vs UK£0.15 loss in 1H 2023)

Arecor Therapeutics plc Presents Positive Data from Phase I Clinical Trial of Ultra-Concentrated, Ultra-Rapid Acting Insulins

Arecor Therapeutics plc to Report Q2, 2024 Results on Sep 23, 2024

Price target decreased by 9.0% to UK£4.18

New minor risk - Shareholder dilution

Arecor Therapeutics plc has completed a Follow-on Equity Offering in the amount of £6.416654 million.

Arecor Therapeutics plc has completed a Follow-on Equity Offering in the amount of £6.416654 million.

Companies Like Arecor Therapeutics (LON:AREC) Are In A Position To Invest In Growth

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Arecor Therapeutics plc, Annual General Meeting, Jun 28, 2024

Consensus EPS estimates upgraded to UK£0.17 loss, revenue downgraded

Arecor Therapeutics plc Announces Its Ultra-Concentrated, Ultra-Rapid Acting Insulins

Full year 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Financial data availability

Price target increased by 12% to UK£5.08

Arecor Therapeutics plc to Report Fiscal Year 2023 Results on May 07, 2024

Arecor Therapeutics plc Announces Stepping Down of Susan Lowther as Chief Financial Officer, Effective from July 22, 2024

Arecor Therapeutics plc Announces Stepping Down of Susan Lowther as Chief Financial Officer, Effective from July 22, 2024

Will Arecor Therapeutics (LON:AREC) Spend Its Cash Wisely?

Arecor Therapeutics plc Provides Update on Progress of Second Phase I Clinical Study of Ultra-rapid, Ultra-Concentrated Insulin Candidate AT278

Consensus EPS estimates fall by 31%

First half 2023 earnings released: UK£0.15 loss per share (vs UK£0.16 loss in 1H 2022)

Arecor Therapeutics plc to Report First Half, 2023 Results on Sep 14, 2023

Arecor Therapeutics plc, Annual General Meeting, Jun 09, 2023

Consensus revenue estimates increase by 10%

Consensus EPS estimates upgraded to UK£0.20 loss, revenue downgraded

Full year 2022 earnings: EPS misses analyst expectations

Aarecor Therapeutics plc Announces Publication of Phase I Data for AT278 in Diabetes Care

Price target decreased to UK£5.20

Arecor Therapeutics plc Commences Second Clinical Trial with At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Candidate for Type 2 Diabetes

Less than half of directors are independent

Arecor Therapeutics plc Announces Headline Results from Phase I Trial of AT247

Arecor Therapeutics plc Presents Positive Data for At278 at Easd

Arecor Therapeutics plc (AIM:AREC) agreed to acquire Tetris Pharma Limited from Xeris Biopharma Holdings, Inc. (NasdaqGS:XERS).

Arecor Therapeutics plc to Report First Half, 2022 Results on Sep 05, 2022

First half 2021 earnings: EPS exceeds analyst expectations

Less than half of directors are independent

Arecor Therapeutics plc to Report Fiscal Year 2021 Results on Apr 25, 2022

Arecor Therapeutics plc to Report Fiscal Year 2021 Results on Apr 25, 2022

Arecor Therapeutics plc Commences the US Phase I Clinical Trial of Arecor's Lead Product, AT247

Arecor Therapeutics plc Announces its Ultra-Concentrated Ultra-Rapid Acting Insulin, At278 Met all of its Primary and Secondary Endpoints with Positive Headline Results from the Phase I Clinical Trial

Less than half of directors are independent

Arecor Therapeutics plc Announces Formulation Study Collaboration with Par Sterile Products, LLC to Develop Stable Ready to Use Product

Arecor Therapeutics PLC has completed an IPO in the amount of £20.000001 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin